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ProstaglandinsProstaglandins (PGs) increase in bone in response to mechanical loading and stimulate bone formation. Inhibi-
tion of cyclooxygenase (COX), the enzyme responsible for PG synthesis, by non-steroidal anti-inﬂammatory
drugs (NSAIDs) impairs the bone formation response to loading in animals when administered before, but not
after, loading. The aim was to determine whether the timing of ibuprofen use (400 mg before versus after exer-
cise sessions) is a signiﬁcant determinant of the adaptive response of BMD to exercise training in older adults.We
hypothesized that taking ibuprofen before exercise would attenuate the improvements in total hip and lumbar
spine BMD in response to 36weeks of trainingwhen comparedwith placebo orwith ibuprofen use after exercise.
Untrained women and men (N = 189) aged 60 to 75 years were randomly assigned to 1 of 3 treatment arms:
placebo before and after exercise (PP); ibuprofen before and placebo after exercise (IP); and placebo before
and ibuprofen after exercise (PI).
The difference between groups in the change in BMD was not signiﬁcant when IP was compared with either PP
(hip,−0.5% (−1.4, 0.4); spine, 0.1% (−0.9, 1.2)) or PI (hip, 0.3% (−0.6, 1.2); spine, 0.5% (−0.5, 1.5)). Ibuprofen
use appeared to havemore adverse effects on BMD inwomen thanmen. The study demonstrated that ibuprofen
use did not signiﬁcantly alter the BMD adaptations to exercise in older adults, but this ﬁnding should be
interpreted cautiously. It had been expected that the inhibition of bone formation by ibuprofen would be more
robust in men than in women, but this did not appear to be the case and may have limited the power to detect
the effects of ibuprofen. Further research is needed to understand whether NSAID use counteracts, in part, the
beneﬁcial effects of exercise on bone.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
Prostaglandin E2 (PGE2) increases in bone in response tomechanical
loading (Chow, 2000; Thorsen et al., 1996) and is an essential signaling
factor for the stimulation of bone formation (Chow, 2000; Zaman et al.,
1997). Cyclooxygenase (COX) is the key enzyme involved in the pro-
duction of prostaglandins. There is compelling evidence from basic
(i.e., osteoblasts) and preclinical (i.e., animals) studies that inhibition of
COX activity by non-steroidal anti-inﬂammatory drugs (NSAIDs)marked-
ly diminishes the bone formation response to mechanical stress (Chow
and Chambers, 1994; Kunnel et al., 2004; Li et al., 2002; Chow et al.,
1998; Cheng et al., 1997; Forwood, 1996). The impaired bone formationEast 19th Avenue, Aurora, CO
.M. Jankowski).response has been found to occurwhen the NSAID is administered before
mechanical loading, but not when it is administered after (Chow and
Chambers, 1994; Li et al., 2002). A limitation of these preclinical studies
was that they evaluated the bone formation response to acute mechan-
ical stress only. One study that utilized a selective COX-2 inhibitor be-
fore loading sessions found that bone adaptations were not impaired
after 2 weeks of mechanical loading (Sugiyama et al., 2013).
In a proof-of-concept study conducted in young women, we found
that the administration of ibuprofen 1 to 2 h before exercise sessions
over 36 weeks of exercise training resulted in the least favorable adap-
tations of bonemineral density (BMD)when comparedwith taking ibu-
profen after exercise or placebo before and after exercise (Kohrt et al.,
2010). In contrast, taking ibuprofen after exercise resulted in relatively
large gains in BMD. Considering that older adults are at increased risk
of osteoporosis and commonly takeNSAIDs to treat commonpain disor-
ders, it is important to determine whether skeletal adaptations to exer-
cise training in this population are inﬂuenced by NSAID use.
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the timing of ibuprofen use relative to the performance of exercise
(before versus after) is a signiﬁcant determinant of the adaptive BMD re-
sponse to exercise training in older adults. We hypothesized that taking
ibuprofen before exercise sessions would attenuate the improvements
in total hip and lumbar spine BMD in response to 36 weeks of exercise
training when compared with placebo and with ibuprofen use after
exercise (i.e., ibuprofen before exercise b placebo or ibuprofen after
exercise). A second aimwas to determinewhether ibuprofen use before
or after exercise inﬂuences changes in fat-free mass (FFM) in response
to exercise training.
2. Materials and methods
2.1. Study design and participants
This was a randomized, double-blinded, placebo-controlled study of
the timing of ibuprofen use relative to exercise on the BMD response to
a 36-week exercise training intervention in healthy older adults. Volun-
teers provided written informed consent to participate in the study,
which was approved by the Colorado Multiple Institutional Review
Board. The trial was registered under ClinicalTrials.gov: NCT00462722.
The participants were women and men (N = 189), aged 60 to 75
years, who had not been performing regular moderate-to-vigorous
weight-bearing or weight-lifting exercise (deﬁned as ≤2 days per
week during the 6months prior to study entry) andwhose average fre-
quency of NSAID (including low-dose aspirin) or acetaminophen use
was b3 days per month. All women were postmenopausal. The exclu-
sion criteria were: relative or absolute contraindications to regular use
of NSAIDs, including history of peptic ulcer or upper gastrointestinal
bleeding, anemia, renal impairment (estimated glomerular ﬁltration
rate (eGFR) b45mL/min/1.73m2), or chronic hepatobiliary disease; os-
teoporosis (lumbar spine, total hip, femoral neck, or trochanter T-score
≤−2.5); diabetes mellitus requiring pharmacologic therapy; conges-
tive heart failure; uncontrolled hypertension (resting systolic pressure
N150 mm Hg or diastolic pressure N90 mm Hg); indicators of ischemic
heart disease or serious arrhythmias at rest or during a graded treadmill
exercise test (GXT); thyroid dysfunction (ultrasensitive thyroid stimu-
lating hormone b0.5 or N5.0 mU/L); orthopedic problems that limited
the ability to perform vigorous exercise; and use of narcotics or medica-
tions known to alter bonemetabolism in the previous 6months. Volun-
teers who met eligibility criteria and were willing to participate in the
study were randomly assigned to 1 of 3 drug treatment arms before
starting the exercise training: 1) placebo before exercise, placebo after
exercise (PP), 2) ibuprofen before exercise, placebo after exercise (IP),
and 3) placebo before exercise, ibuprofen after exercise (PI). The ran-
domization was stratiﬁed by sex to ensure similar distribution of
women and men across treatment arms.
2.2. Drug intervention
Participantswere instructed to take one study capsule 1 to 2 h before
exercise and one study capsule immediately after on each day of super-
vised exercise. The capsuleswere prepared by a local pharmacy (Belmar
Pharmacy, Lakewood, CO, USA) and contained either ibuprofen 400 mg
or inactive ingredients; ibuprofen content was conﬁrmed by an inde-
pendent laboratory.
All capsules were identical in appearance, with the exception
that capsules taken before exercise sessions were green and those
taken after were red. Participants recorded the time that the pre-
exercise capsule was taken when they arrived at the laboratory for an
exercise session. The post-exercise capsule was taken immediately
upon completion of the exercise session and the time was recorded. A
research pharmacist managed the randomization process, maintained
all drug intervention records, and prepared and dispensed study drug
packets.2.3. Exercise intervention
All participants engaged in a 36-week supervised progressive exer-
cise program. They were asked to complete a minimum of 3 sessions
per week. The goal of the training was to increase BMD using high-
intensity resistance exercise and other weight-bearing exercises that
generated relatively high bone-loading forces (e.g., ﬂoor jumps, stair
climbing/descending). Each exercise session included 3 sets each of 7
resistance exercises, 2 sets of ﬂoor jumping activities, and 1 set of stair
climbing/descending. The resistance exercises were initially performed
at a moderate intensity (60% to 70% of 1-repetition maximum (1RM);
3 sets of 8 to 12 repetitions). Resistance was progressively increased
to the goal of 80% of 1RM (2 sets of 5 to 8 repetitions after 1 warm-up
set at a lower intensity). Two resistance exercise plans were performed
on alternating days (plan A: lateral pull down, bench press, hip abduc-
tion and adduction, biceps curls, seated row, and assisted chin-ups;
plan B: overhead press, leg press, tricep extension, knee extension and
ﬂexion, heel raise, and shoulder external rotation). The ﬂoor jumping
sets included jumping jacks and multidirectional 4-square jumps with
two-footed landings. Participants completed patterns of forward, back-
ward, lateral, and diagonal movements on a 4-square diagram on the
ﬂoor. Stair climbing/descending took place in a stairwellwith a handrail.
The number of jumps and stair ﬂights was increased approximately
every two weeks, beginning conservatively with 2 sets of 6 jumps and
4 stair ﬂights (12 steps/ﬂight) and progressing to 2 sets of 30 jumps
and 15 stair ﬂights. Each exercise session began and ended with a
5-minute treadmill walk. The total exercise time was approximately
60 min per session, excluding the warm-up and cool-down.
2.4. Dietary supplements
Combination calciumcitrate (630mg/day) and vitaminD (400 IU/day)
supplements were provided to all participants. They were instructed to
take one tablet (315mg/200 units) twice daily throughout the 36-week
intervention. If a participant was already taking a calcium supplement,
the home supplement was discontinued.
2.5. BMD and body composition
At baseline and after 36 weeks of training, BMD of the proximal
femur (total and neck, trochanter, and subtrochanteric regions) and
lumbar spine (L1–4), fat-free mass (FFM), and fat mass were measured
by dual-energy X-ray absorptiometry (DXA) using a Hologic Discovery
W instrument (version 12.6; Hologic, Inc., Bedford, MA). In our labora-
tory, the coefﬁcients of variation (CVs) for lumbar spine, total hip,
femoral neck, trochanter, and subtrochanter BMD are (mean (SD))
1.2% (0.8%), 0.8% (0.6%), 1.9% (0.9%), 1.5% (1.0%), and 1.1% (0.6%). CVs
for FFM and fat mass are 1.2% (0.8%) and 1.8% (0.9%), respectively. Hip
and spine images that included metal implants were excluded from
the BMD analyses. DXA scan reports were reviewed by two investiga-
tors for quality assurance.
2.6. Safety monitoring
A monthly health status survey was administered that included
questions about recent illnesses, visits to a clinician, hospitalizations,
changes in over-the-counter and prescription drugs, and perception of
overall health. Blood samples were drawn every 3 months to monitor
study-speciﬁc adverse events, deﬁned as: 1) decrease in hemoglobin
(Hb) to below the sex-speciﬁc lower limit of normal or a decrease of
N3 g/dL from baseline; 2) impaired liver function, deﬁned as an increase
in AST or ALT to more than 1.5 times the upper limit of normal; 3) de-
crease in renal function, deﬁned as an increase in serum potassium to
N5.5mmol/L, increase in resting blood pressure to N180mmHg systolic
or N100mmHgdiastolic, or decrease in eGFR to b40mL/min/1.73m2 or
a decrease of 25% or more from baseline.
Fig. 1. Recruitment, enrollment, and retention of study volunteers.
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lieving medications since the last exercise session in their exercise log.
For the relief of discomfort or pain, subjects were instructed to use ice,
heat, or over-the-counter topical creams containing only menthol, cap-
saicin, or salicylates with very low systemic absorption (e.g., trolamine
salicylate) as ﬁrst line therapy. If ineffective, second line therapy was
methyl salicylate creams or acetaminophen, and third line therapy
was oral NSAIDs.
2.7. Statistical analyses
We hypothesized that the timing of ibuprofen use relative to exer-
cise would be a signiﬁcant determinant of the changes in BMD
(IP b PP or PI). The primary outcomes were the 36-week changes in
total hip and lumbar spine BMD. Sample size requirements for the pri-
mary outcomes were estimated from a pilot study in which young
women underwent 36 weeks of exercise training and were treated
with IBUP 400 mg before or after exercise sessions (IP vs PI; n = 10
per group). It was estimated that 40 evaluable subjects per group
would provide 90% power to detect a difference between any two treat-
ment groups of 1.14% for lumbar spine BMD and 1.44% for total hip
BMD, based on a 2-sided test at an alpha level of 0.05 or less. To allow
for attrition, the plan was to randomize 150 participants (50 per
group). Although the pilot study on which statistical power was based
included only women, we expected that the inclusion of men would
magnify the effect of ibuprofen before exercise to inhibit an increase
in BMD. This was based on the observation that use of COX-2 selective
inhibitors had amore harmful effect on BMD inmen than in postmeno-
pausal women (Richards et al., 2006).
Participant characteristics at baseline were compared across groups
by one-way ANOVA for continuous measures or chi-squared tests of
equal proportions for categorical variables. The effects of timing of ibu-
profen relative to exercise were evaluated by analysis of covariance
(ANCOVA) regressing the percent change from baseline to 36 weeks
in the outcome measure on the baseline value, sex (because it was a
stratiﬁcation variable), and an indicator for treatment group. The prima-
ry intention-to-treat (ITT) analyses compared the differences in the
changes in outcome measures between 1) IP and PP; and 2) IP and PI.
The analyses were repeated for subgroups of participants who were
compliant to exercise (attended at least 80% of exercise sessions) and
drug (reported taking at least 80% of prescribed doses). Comparisons
were considered signiﬁcant at p = 0.05 or less. Post-hoc analyses of
the percent changes from baseline to 36 weeks in total hip, hip regions,
and lumbar spine within each treatment group were performed using
one sample t-tests. Because these were not primary outcomes of the
trial, changes are presented with raw p values adjusted for multiple
comparisons using Benjamini and Hochberg's false discovery rate,
(FDR) (Benjamini and Hocberg, 1995). Data are presented as mean
(SD), unless otherwise speciﬁed.
2.8. Drug dispensation error
In the third year of the trial, a drug dispensation error occurred that
resulted in ibuprofen being dispensed in place of placebo for the before-
exercise dosing for some study participants. It was subsequently deter-
mined by weighing capsules that the product used for placebo capsules
was less dense than ibuprofen, resulting in placebo capsules weighing
less than ibuprofen capsules in a consistent manner. All participants
had returned unused capsules from study drug dispensations, so these
capsuleswereweighed to determinewhohad received correct or incor-
rect studydrugs and atwhat points in the intervention. A total of 39 par-
ticipants were affected by the dispensing error and could be categorized
into 3 groups: 1) 25 received inconsistent dispensations during the
intervention (excluded from the primary analyses); 2) 3 received con-
sistent dispensations that were different from their randomized assign-
ment but were 1 of the 3 treatment arms (included in the primaryanalyses based upon their reassigned arm); and 3) 11 received the
incorrect treatment during the ﬁrst dispensation period (e.g., weeks
1–12) and were invited to extend the intervention by 12 weeks so
that they would undergo 36 weeks of training with the correct treat-
ment (6 did so and were included in the primary analyses). Double-
blindingwasmaintained during the time of the drug dispensation error.
Because of the drug dispensation error, 39 new participants (total of
189) were randomized to treatment (Fig. 1). The drug dispensation
error resulted in 30 cases being excluded from further analyses. Of the
159 remaining participants, 29 were lost to follow-up. When compared
to those lost to follow-up (7men, 22 women), the ﬁnishers (48men, 82
women) had lower fatmass (28.0 (8.0) vs 31.6 (8.7) kg; p= 0.030) and
were taller (170 (10) vs 160 (10) cm; p = 0.033). The baseline charac-
teristics of participants included in the ITT analyses were well matched
across groups (Table 2), although there was a difference in the propor-
tion of Caucasians. Study attrition differed among the groups (p =
0.020), with the IP group having a higher proportion of ﬁnishers than
the other groups (IP, 93%; PP, 74%; PI 78%).
3. Results
Participants whoﬁnished the intervention (48men, 82women) had
lower fat mass (28.0 (8.0) vs 31.6 (8.7) kg; p = 0.030) and were taller
(170 (10) vs 160 (10) cm; p = 0.033) when compared to those lost to
follow-up (7 men, 22 women). The baseline characteristics of partici-
pants included in the ITT analyses were well matched across groups
(Table 1). Study attrition differed among the groups (p = 0.020), with
the IP group having a higher proportion of ﬁnishers than the other
groups (IP, 93%; PP, 74%; PI 78%).
3.1. Exercise intervention
There were no signiﬁcant differences (all p N 0.300) among the
groups in the amount of exercise performed during the intervention
Table 1








Females 23 (62) 32 (63) 27 (64) 0.979
Caucasian 33 (89) 47 (92) 35 (83) 0.418
Hispanic 2 (5) 2 (4) 1 (2) 0.779
Age, years 64 (4) 64 (4) 66 (4) 0.079
BMI, kg/m2 28 (5) 27 (5) 27 (4) 0.586
Height, m 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) 0.726
Weight, kg 79.1 (16.3) 79.0 (17.0) 77.7 (14.8) 0.901
Fat mass, kg 28.4 (8.4) 28.2 (8.6) 27.3 (6.9) 0.822
Fat-free mass, kg 50.8 (12.5) 50.8 (12.0) 50.3 (11.7) 0.980
BMD, g/cm2
Lumbar spine 1.021 (0.139) 1.035 (0.248) 1.023 (0.176) 0.938
Total hip 0.934 (0.125) 0.904 (0.132) 0.942 (0.157) 0.377
Femoral neck 0.752 (0.107) 0.728 (0.094) 0.784 (0.142) 0.075
Trochanter 0.709 (0.103) 0.691 (0.110) 0.718 (0.148) 0.556
Subtrochanter 1.107 (0.151) 1.078 (0.161) 1.118 (0.172) 0.468
Values are number of subjects (%) or mean (SD).
a 3 participants had uninterpretable hip scans (1 placebo/placebo, 2 ibuprofen/placebo)
and 1 had an uninterpretable spine scan (ibuprofen/placebo).
Fig. 2. Relative changes in BMD, adjusted for baseline BMD, in response to 36 weeks of
exercise training in older adults who took ibuprofen 400 mg before (ibuprofen/placebo)
or after (placebo/ibuprofen) exercise sessions or placebo at both time points (placebo/
placebo). The error bars represent SD.
4 C.M. Jankowski et al. / Bone Reports 1 (2015) 1–8(i.e., weight lifted, jumps and stair ﬂights completed; data not shown).
In training weeks 5 to 8 (after familiarization with the equipment),
the number of sessions completed per week was (mean (SD)) 3.3
(0.8), 3.5 (0.7), and 3.5 (0.7) in the IP, PP, and PI groups, respectively
(p= 0.255). In training weeks 29 to 32 (before ﬁnal testing), the num-
ber of sessions completed perweekwas 2.9 (0.8), 2.8 (0.8), and2.7 (0.8)
in the IP, PP, and PI groups, respectively (p = 0.523). The amount of
weight lifted and number of jumps and stair ﬂights completed increased
from weeks 5–8 to weeks 29–32 (Table 2; all p b 0.001).
Exercise sessions lasted approximately 1 h. The time between the
before- and after-exercise doses of study drug averaged 2.9 (0.7) h, in-
dicating that participants were taking the before-exercise dose approx-
imately 2 h before exercise, as instructed.
3.2. Intention-to-treat analysis
3.2.1. Changes in BMD (Figs. 2 and 3, Table 3)
We hypothesized that changes in lumbar spine and hip BMD would
be reduced in the IP group when compared with both the PP and PI
groups, but this was not supported (Fig. 2, Table 3). The PP group had
the most favorable adaptations in hip BMD, but differences between
the groups did not reach statistical signiﬁcance. None of the within-
group changes was statistically signiﬁcant after adjusting for multiple
comparisons (Benjamini andHocberg, 1995). In the PP group, trochanterTable 2
Average exercise training volume after familiarization to the equipment (weeks 5 to 8) and be
Weeks 5 to 8
Repetitions per set Weight per session, lb
Resistance exercises
Leg extension 8 (2) 1182 (598)
Leg ﬂexion 9 (2) 1520 (734)
Leg press 9 (2) 4183 (1851)
Hip abduction 9 (2) 1874 (773)
Hip adduction 9 (2) 2061 (913)
Lateral pulldown 8 (2) 2272 (961)
Bench press 8 (1) 1236 (803)
Overhead press 8 (1) 987 (530)
Biceps curlc 8 (2) 632 (265)
Tricep extensionc 9 (2) 386 (205)
Seated row 8 (2) 1481 (668)
Jumps/session 36 (17)
Stair ﬂights/session 7 (3)
Values are mean (SD).
a Increase from weeks 5 to 8, p b 0.001.
b One outlier was removed from the analysis; if included, the increase was 47 (227)%.
c Performed unilaterally.BMD increased 1.2% (3.2%) (unadjusted p=0.037; adjusted p=0.262).
In the IP group, lumbar spine BMD increased 1.4% (5.1%) (unadjusted
p = 0.05; adjusted p = 0.262). In the PI group, lumbar spine BMD in-
creased 2.0% (4.3%) (unadjusted p = 0.008; adjusted p = 0.128).
Although the study was not powered to detect sex differences, we
evaluated changes in BMD in women and men separately in secondary
analyses (Fig. 3). Within each sex, there were no signiﬁcant differences
among the groups in the change in BMD at any skeletal region. Ibupro-
fen use either before or after exercise appeared to have a more deleteri-
ous effect (albeit nonsigniﬁcant) on hip, trochanter, and subtrochanter
BMD in women than in men.
3.2.2. Changes in body composition (Table 4)
The average increases in FFM in response to exercise training were
0.4 to 0.6 kg across groups and the average decreases in fat mass were
−0.9 to−1.1 kg. There were no signiﬁcant effects of ibuprofen use be-
fore or after exercise on the changes in body composition in response to
exercise training.
3.3. Adherence analyses
Adherence to the study drugs averaged 89% (18%) for the pre-
exercise study doses and 96% (15%) for the post-exercise doses. The
subgroup that was adherent to drug included 34 participants in the
PP group, 38 in the IP group, and 35 in the PI group (p = 0.092). Thefore ﬁnal testing (weeks 29 to 32).
Weeks 29 to 32 Increase, %
Repetitions per set Weight per session, lb Weight per session, lb
8 (2) 1498 (673)a 32 (30)
8 (2) 1873 (751)a 29 (29)
9 (2) 5264 (2112)a 26 (23)b
8 (1) 2263 (729)a 23 (22)
8 (2) 2679 (1066)a 39 (89)
8 (2) 2820 (1103)a 24 (24)
8 (2) 1589 (938)a 32 (34)
7 (2) 1215 (550)a 26 (25)
8 (2) 789 (333)a 26 (33)
8 (2) 607 (254)a 67 (48)
8 (1) 1837 (735)a 25 (23)
65 (30) 101 (77)
15 (6) 141 (80)
Fig. 3. Relative changes in BMD, adjusted for baseline BMD, in response to 36 weeks of
exercise training in women (top panel) and men (bottom panel) who took ibuprofen
400 mg before (ibuprofen/placebo) or after (placebo/ibuprofen) exercise sessions or pla-
cebo at both time points (placebo/placebo). The error bars represent SD.
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in the IP group, and 38 in the PI group (p= 0.389). Secondary analyses
were conducted in the subgroups that were adherent to drug and/or
exercise. The results of these analyses (data not shown) were similar
to those of the ITT analyses.
3.4. Adverse events
There were no adverse events based on the criteria for changes in
hemoglobin, liver function, serum potassium, blood pressure or self-
reported symptoms. One participant had a decrease in eGFR of greater
than 25% that triggered the discontinuation of study drug. However,
on average, there were decreases in eGFR in all groups that were
small in magnitude and similar in placebo- and ibuprofen-treated
participants.
4. Discussion
The intent of this studywas to determinewhether the use of ibupro-
fen before exercise diminished improvements in BMD in response toTable 3
Relative changes (%) in bone mineral density within groups and the between-group difference
PPa IPa
Mean (SD)
Lumbar spine 1.3 (2.8) 1.5 (2.5)
Total hip 0.5 (2.6) 0.0 (1.9)
Femoral neck 0.2 (2.9) 0.2 (2.8)
Trochanter 1.1 (3.1) 0.0 (2.3)
Sub-trochanter 0.5 (3.4) 0.0 (2.3)
PP, placebo before and placebo after exercise; IP, ibuprofen before and placebo after exercise; P
a 3 participants had uninterpretable hip scans (1 placebo/placebo, 2 ibuprofen/placebo) andexercise training. The mechanistic basis for the study was the evidence
in animals that the bone formation response to mechanical loading is
markedly impaired when NSAIDs are present before loading, but not
when NSAIDs are introduced after loading (Chow and Chambers,
1994; Li et al., 2002). Accordingly, the hypothesis was that increases in
BMDwould be lessened by the use of ibuprofen before exercise sessions
when compared with either no ibuprofen use or with ibuprofen use
after exercise sessions (i.e., IP b PP, PI). The most favorable changes in
BMD tended to occur in the PP group, but there were no signiﬁcant dif-
ferences among the groups in the BMD responses to exercise training.
However, because this was the ﬁrst trial of the effects of NSAID use on
skeletal adaptations to exercise in older adults, the results should be
interpreted cautiously.
4.1. Preclinical evidence for effects of NSAIDs on bone formation
To our knowledge, Chow and Chambers were the ﬁrst to observe
that the timing of NSAID administration relative to mechanical loading
inﬂuenced the bone formation response (Chow and Chambers, 1994).
In that study, a single dose of indomethacin administered to 3-month-
old female rats 3 h before loading reduced the bone formation response
by 65% when compared with vehicle treatment, but only 20%when ad-
ministered 6 h after loading. In a similar experiment (Li et al., 2002), the
loading-stimulated bone formation rate in 7-month-old female rats was
signiﬁcantly reduced when a COX-2 selective inhibitor was injected
180 min (−70%) or 30 min (−45%) before loading, but not when
given 30 min after (−20%) loading. We are not aware of any studies
that have evaluated sex differences in these responses or whether re-
sponses are different in young adult versus aged animals.
A limitation of the studies of animals (Chow and Chambers, 1994; Li
et al., 2002) was that they evaluated bone responses to only a single
loading event. Because prostaglandins can stimulate both bone resorp-
tion and formation, the net effects of NSAIDs on bone adaptations to re-
peated mechanical loading could be beneﬁcial, detrimental, or neutral
(Blackwell et al., 2010). We are aware of only one published study of
the inﬂuence of NSAIDs on adaptations of bone to repeated episodes
of mechanical loading (Sugiyama et al., 2013). In 19-week-old female
mice, a COX-2 selective inhibitor administered 3 h before loading ses-
sions did not attenuate the gains in trabecular or cortical bone induced
by 2 weeks of mechanical loading. The relevance of this ﬁnding to
the current study is uncertain for the following reasons. First, the
study was conducted in young adult female mice and responses may
be inﬂuenced by age and/or sex. Second, the effects of a COX-2 inhibitor
on skeletal adaptations to loading may be different from effects of non-
selective inhibitors, such as ibuprofen. Although it is COX-2 that is be-
lieved to mediate the bone formation response to loading, mice with a
null mutation of the COX-2 gene had a normal response to loading
that appeared to be mediated by an up-regulation of COX-1 (Alam
et al., 2005). Finally, it is not clear whether external mechanical loading
mimics the pro-inﬂammatory effects of vigorous exercise (Gleeson,
2007). If it does not, there could be differential effects of NSAIDs on
skeletal adaptations to exercise (humans) versus external mechanical
loading (animals) because of the pro-resorption effects of inﬂammatory
cytokines (Redlich and Smolen, 2012). Alternatively, if the externals in the responses adjusted for baseline values and sex.
PI IP–PP IP–PI
Mean (95% CI)
0.9 (2.2) 0.1 (−0.9, 1.2) 0.5 (−0.5, 1.5)
−0.3 (2.0) −0.5 (−1.4, 0.4) 0.3 (−0.6, 1.2)
−0.1 (2.1) 0.0 (−1.2, 1.1) 0.2 (−0.9, 1.3)
−0.1 (2.7) −1.1 (−2.3, 0.0) 0.1 (−1.0, 1.2)
−0.3 (2.5) −0.6 (−1.8, 0.6) 0.2 (−0.9, 1.4)
I, placebo before and ibuprofen after exercise.
2 participants had uninterpretable spine scans (2 ibuprofen/placebo).
Table 4
Changes in body composition (kg) in response to exercise training conditioned on baseline values and sex.
PP (n = 37) IP (n = 51) PI (n = 42) IP–PP IP–PI
Weight −0.5 (1.1) −0.9 (4.2) −0.3 (3.1) −0.4 (−1.7, 1.0) −0.5 (−1.8, 0.8)
Fat-free mass 0.6 (1.1) 0.4 (1.6) 0.6 (1.4) −0.1 (−0.7, 0.5) −0.1 (−0.7, 0.4)
Fat mass −1.1 (1.5) −1.3 (3.3) −0.9 (2.6) −0.3 (−1.4, 0.7) −0.4 (−1.4, 0.7)
Values are mean (SD or 95% CI).
PP, placebo before and placebo after exercise; IP, ibuprofen before and placebo after exercise; PI, placebo before and ibuprofen after exercise.
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may have reduced inﬂammation and attenuated joint damage (Poulet
et al., 2011; Ko et al., 2013), leading to greater cage activity and thereby
negating the detrimental effects of NSAIDs on bone formation.
4.2. NSAID use and BMD in humans
Observational studies suggest that NSAID use can have beneﬁcial
effects on BMD in older adults (Morton et al., 1998; Bauer et al., 1996;
Carbone et al., 2003; Vestergaard et al., 2012). In these studies, BMD
tended to be similar or higher in women (Morton et al., 1998; Bauer
et al., 1996; Carbone et al., 2003; Vestergaard et al., 2012) and men
(Carbone et al., 2003) who reported using NSAIDs when compared
with those who did not. One study that included both women and
men evaluated associations of BMD with use of COX-1 or COX-2 selec-
tive inhibitors, with or without aspirin use (Carbone et al., 2003). The
results were not presented separately for women and men, but sex
was included as a covariate. The major ﬁnding was that hip BMD was
higher in older adults who used both a COX-2 inhibitor and aspirin
than in nonusers (4.6%). Only those who used a COX-2 inhibitor alone
had a lower BMD than nonusers (−1.6%), but the difference was not
statistically signiﬁcant.
The Canadian Multicentre Osteoporosis Study also evaluated the as-
sociations of BMD with use of COX-2 inhibitors, and reported results
separately for men, women on menopausal hormone therapy (HT),
and women not on HT (Richards et al., 2006). Daily use of COX-2 inhib-
itors was associated with lower proximal femur and spine BMD in men
(ranging from−5% to−2% across regions), but greater proximal femur
BMD in postmenopausal women not on HT (ranging from 1% to 6%
across regions). Use of COX-2 inhibitors was associated with greater
spine, but not hip, BMD in postmenopausal women on HT. The
authors suggested that the net effect of COX-2 inhibitors on BMD is
likely determined by the dominant actions of NSAIDs to 1) reduce
inﬂammation-mediated bone loss (i.e., anti-resorption effect), and/or
2) block mechanical load-related bone gain (i.e., anti-formation effect).
They speculated that the lower BMD levels in men using COX-2 inhibi-
tors reﬂected an inhibition of the skeletal beneﬁts of mechanical
loading, whereas the higher BMD in women not on HT reﬂected an at-
tenuation of inﬂammation-mediated resorption. This interpretation
was consistent with the ﬁnding in our proof-of-concept study in pre-
menopausal women (Kohrt et al., 2010) that use of NSAIDs after exer-
cise seemed to amplify the increase in BMD. We speculated that use
of NSAIDS after exercise would 1) allow a normal bone formation re-
sponse, because introducing NSAIDs before, but not after, loading im-
pairs bone formation in animals (Chow and Chambers, 1994; Li et al.,
2002) and 2) attenuate inﬂammation-induced bone resorption, thereby
3) inﬂuencing the balance between formation and resorption in a man-
ner that favors formation.
Based on the ﬁndings from the Canadian Multicentre Osteoporosis
Study (Carbone et al., 2003) and our proof-of-concept study of NSAID
use and exercise in youngwomen (Kohrt et al., 2010), we had expected
that the beneﬁt of NSAID use after exercise to increase BMD would
be even greater in older adults than in young women because of the
greater potential to reduce inﬂammation-related bone resorption in
the former. We had also expected that the potential effect of NSAID
use before exercise to attenuate increases in BMD by inhibiting boneformation would be more pronounced in men than in women because
of greater anabolic potential in men. Neither of these expectations was
realized. Although differences did not reach statistical signiﬁcance,
there was no signal for a beneﬁt of NSAID use after exercise to enhance
increases in BMD, as we had observed previously in young women
(Kohrt et al., 2010). Further research will be needed to determine
whether NSAID use either before or after exercise impairs the BMD ad-
aptations in some regions of the proximal femur (Fig. 2), particularly in
women (Fig. 3). To our knowledge, whether age and/or sex inﬂuence
the effects of NSAIDs on bone adaptations to loading has not been inves-
tigated in animal models.
Importantly, study attrition was signiﬁcantly lower in the group
that took NSAIDs before exercise (7%) than in the other two groups
(22%, 26%). This suggests that taking NSAIDs before exercise improves
the ability to tolerate the type of vigorous exercise that can increase
bonemass and strength. In animal models, repetitive intermittent com-
pressive bone loading over several weeks induced articular cartilage
damage characteristic of osteoarthritis (Poulet et al., 2011; Ko et al.,
2013; Warner et al., 2002). It is possible that NSAID use before exercise
alleviates joint pain in older adults and contributes to better exercise
tolerance. Because exercise is recommended for the prevention of oste-
oporosis, it is important to understandwhether the beneﬁts are blocked
by NSAID use. Further research will be necessary to determine if the ef-
fects of NSAIDs to impair or augment skeletal adaptations to exercise are
inﬂuenced by such factors as age, sex, and the type and dose of NSAID.
4.3. NSAID use and fat-free mass
There is a paucity of research on the effects of NSAIDs on skeletal
muscle metabolism. At the time the current trial was initiated, it had
been demonstrated that ibuprofen reduced the increase in fractional
muscle protein synthesis following high-intensity resistance exercise
by more than 50% (Trappe et al., 2002). Expression of prostaglandin E2
and F2α in muscle tissue was also blunted in ibuprofen-treated men
when compared with placebo-treated controls (Trappe et al., 2001).
This led us to hypothesize that the increase in fat-freemasswould be re-
duced in the group that took NSAIDs before each exercise session when
compared with the placebo group. However, this did not occur, as the
increases in fat-free mass were not signiﬁcantly different among the
3 treatment groups. The same investigators who found that ibuprofen
impaired acute muscle responses to exercise in young men (Trappe
et al., 2001, 2002) subsequently reported that ibuprofen augmented
the gains in muscle volume and strength after 12 weeks of resistance
exercise training in olderwomen andmen (Trappe et al., 2011). Because
prostaglandins are involved in the regulation of both anabolic and cata-
bolic processes in skeletal muscle (Rodemann and Goldberg, 1982),
the investigators speculated that protein breakdown was attenuated
by ibuprofen to a greater extent than protein synthesis, thereby aug-
menting protein accretion.
The failure of NSAIDs in the current study to augment gains in mus-
cle mass and strength as observed by others (Trappe et al., 2011) was
not related to the age or sex of the participants; both studies included
older women and men. However, a notable difference between the
studies was the dosing of NSAIDs. In the previous study ibuprofen was
taken daily at a dose of 1200 mg, whereas in the current study it was
taken only on exercise days at a dose of 400 mg. If ibuprofen augments
7C.M. Jankowski et al. / Bone Reports 1 (2015) 1–8the exercise-induced gain in muscle mass by suppressing chronic
inﬂammation-related muscle catabolism, it is possible that the low
dosing used in the current study was not sufﬁcient to suppress muscle
protein breakdown.
4.4. Safety
Potential adverse events related to NSAID use were monitored
through health status questionnaires administered every 4 weeks and
blood tests obtained every 12 weeks. The only adverse event that trig-
gered the criterion for stopping drug in an individual was a decrease
in eGFR, which occurred in the IP group. However, on average eGFR de-
clined similarly during the intervention in all three treatment groups, so
it was not clear whether the event was related to ibuprofen use.
4.5. Limitations
The study did not include a no-exercise control group. However, in
the absence of intervention, the trajectory of change in hip BMD in
older adults is downward; small increases in spine BMD can occur as
the result of compression fractures or extravertebral ossiﬁcation. In
our previous study of placebo versus dehydroepiandrosterone therapy
in women and men 60 to 80 years of age (Jankowski et al., 2006), the
average changes in lumbar spine and hip BMD in the placebo group
were+0.4% and−0.4%, respectively, versus+1.3% and+0.5%, respec-
tively, in the current study. This supports the idea that the observed
changes were attributable to the exercise.
The variability of the BMD responses to NSAIDs and exercise was
greater in older adults than in our previous study of young women;
data from that study were used to calculate statistical power. Using
the SD of the percent change in hip BMD from the current study
(2.15%) a between-group difference of 1% would have been signiﬁcant
at the p = 0.05 level with 40 subjects per group; the largest observed
difference was 0.5%. Similarly, using the SD of the change in FFM for
the current study (1.39 kg) a between-group difference of 0.9 kg
would have been signiﬁcant at the 0.05 level; the largest observed differ-
encewas 0.1 kg. It was assumed thatmenwould respond similarly based
on the observation that BMD is low in men who use COX-2 inhibitors
and that the mechanism of action is likely to be an impaired response
to mechanical stimulation (Carbone et al., 2003). Although secondary
analyses of sex differences did not yield signiﬁcant differences, the re-
sults suggested that sex differences should bemore rigorously evaluated
(Fig. 3). The variability in responses between women and men was
greater than expected and this may have limited the ability to detect
signiﬁcant effects of NSAIDs.
The results of the studymay be speciﬁc to ibuprofen and not to other
NSAIDs. Factors that could be important to consider for future research
include the relative COX selectivity and the half-life of theNSAID. Ibupro-
fenwas selected for this trial because it 1) iswidely used, 2) inhibits both
COX-1 andCOX-2 and at the dose used should inhibit the activity of both
isozymes by 80% (Capone et al., 2007); thismay be important if there is a
compensatory increase in COX-1 when COX-2 is inhibited (Alam et al.,
2005), and 3) has a short half-life (approximately 2 h) (Davies, 1998),
which reduced the likelihood that dosing after an exercise session
would have residual effects on exercise performed the following day.
4.6. Summary
In older adults, taking NSAIDs either 2 h before or immediately after
exercise sessions did not signiﬁcantly attenuate or augment the effects
of a 36-week exercise training program on BMD or fat-free mass.
Because this was the ﬁrst randomized controlled trial to investigate
whether NSAIDs inﬂuence musculoskeletal adaptations to exercise,
the negative results should be interpreted cautiously. The patterns of
change in BMDdid not convincingly demonstrate thatNSAIDsdonot di-
minish the skeletal beneﬁts of exercise in older adults. It has beenestimated that more than 29 million adults in the U.S. were regular
users of NSAIDs in 2010, which was 41% higher than in 2005 (Zhou
et al., 2013) and, although data are sparse, the prevalence of use is likely
to be very high in people who exercise regularly (Warner et al., 2002;
Gorski et al., 2011; Holmes et al., 2013). The widespread use of NSAIDs,
coupled with the essential role of exercise in maintaining bone health,
underscore theneed for further research to understandwhetherNSAIDs
diminish the beneﬁcial effects of exercise on bone.
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